Akari Therapeutics (NASDAQ:AKTX) Now Covered by Analysts at StockNews.com

Research analysts at StockNews.com started coverage on shares of Akari Therapeutics (NASDAQ:AKTX) in a report issued on Tuesday. The brokerage set a “sell” rating on the biopharmaceutical company’s stock.

Akari Therapeutics Trading Up 6.0 %

Shares of AKTX opened at $3.34 on Tuesday. The stock’s 50 day moving average is $3.87 and its two-hundred day moving average is $4.19. Akari Therapeutics has a twelve month low of $2.81 and a twelve month high of $23.80. The firm has a market capitalization of $12.42 million, a PE ratio of -0.48 and a beta of 1.40.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently added to or reduced their stakes in the company. Sabby Management LLC increased its position in Akari Therapeutics by 116.5% during the first quarter. Sabby Management LLC now owns 7,941,867 shares of the biopharmaceutical company’s stock worth $1,443,000 after purchasing an additional 4,273,528 shares during the last quarter. Cerity Partners LLC purchased a new stake in shares of Akari Therapeutics during the 2nd quarter valued at $55,000. Renaissance Technologies LLC increased its holdings in shares of Akari Therapeutics by 411.4% during the 1st quarter. Renaissance Technologies LLC now owns 283,550 shares of the biopharmaceutical company’s stock worth $52,000 after buying an additional 228,100 shares during the last quarter. Finally, LPL Financial LLC purchased a new position in shares of Akari Therapeutics in the 2nd quarter worth $83,000.

Akari Therapeutics Company Profile

Akari Therapeutics, Plc, a clinical-stage biopharmaceutical company, focuses on developing advanced therapies for autoimmune and inflammatory diseases. Its lead product candidate is nomacopan, a second-generation complement inhibitor that prevents inflammatory and prothrombotic activities, including paroxysmal nocturnal hemoglobinuria, Guillain-Barré syndrome, hematopoietic stem cell transplant-associated thrombotic microangiopathy, and bullous pemphigoid, as well as pre-clinical program developing long-acting PASylated-nomacopan for treatment of geographic atrophy secondary to dry age-related macular degeneration.